Combination Therapy Produced Strong Results for Late-Stage Ovarian Cancer Patients

Late-stage ovarian cancer patients responded well to an experimental carboplatin/decitabine combination therapy, even though they had become resistant to carboplatin, Indiana University researchers report. Furthermore, the researchers believe they have discovered biomarkers that could assist in identifying patients who are most likely to benefit from this therapy. 

The carboplatin/decitabine drug combination produced a positive result in 70% of patients in this phase 2 trial. The combination was tolerated well and did not produce any dose-limiting toxicities. In 12 of 17 carboplatin-resistant patients whose cancer was progressing, tumor growth slowed considerably or stopped altogether patients following treatment with the experimental drug combination. Moreover, 1 woman’s tumor became undetectable; however, at 336 days her cancer progression resumed. At 6 months, 9 women were still in remission.

Related Items
Cediranib-Based Combination Therapy Extends Progression-Free Survival in Relapsed Ovarian Cancer
Wayne Kuznar
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Gynecologic Cancers, Online First
PARP Inhibitor Veliparib Active in Recurrent BRCA-Positive Ovarian Cancer
Charles Bankhead
TOP - October 2014, Vol 7, No 4 published on October 30, 2014 in Gynecologic Cancers
Bevacizumab Appears to Benefit High-Risk Patients
Alice Goodman
TOP - February 2014, Vol 7, No 1 published on March 1, 2014 in Gynecologic Cancers
Trebananib in Platinum-Sensitive Ovarian Cancer
Alice Goodman
TOP - February 2014, Vol 7, No 1 published on March 1, 2014 in Gynecologic Cancers
Antiangiogenesis Pursued in High-Risk Ovarian Cancer
Alice Goodman
TOP - February 2014, Vol 7, No 1 published on March 1, 2014 in Gynecologic Cancers
Bevacizumab in the Treatment of Advanced Ovarian Cancer
Quan Li, PharmD, BCOP
TOP - October 2012 VOL 5, NO 7 published on November 9, 2012 in Gynecologic Cancers
Skin Cancer Screening at Your Fingertips
TON - Daily published on July 18, 2012 in Gynecologic Cancers
Combination Therapy Produced Strong Results for Late-Stage Ovarian Cancer Patients
TON - Daily published on August 4, 2011 in Gynecologic Cancers
Developments in the Management of Ovarian Cancer
Mauri Markman, MD
TOP - MAY 2011, VOL 4, NO 3 published on May 11, 2011 in Gynecologic Cancers
Telephone Support Increases Adherence to IV Chemotherapy for Recurrent Ovarian Cancer
Fran Lowry
Web Exclusives published on December 10, 2010 in Gynecologic Cancers, In the News
Last modified: April 27, 2020